1. Clinical features and predictive biomarkers for bladder cancer in patients with type 2 diabetes presenting with haematuria.
- Author
-
Tonry CL, Evans RM, Ruddock MW, Duggan B, McCloskey O, Maxwell AP, O'Rourke D, Boyd RE, Watt J, Reid CN, Curry DJ, Stevenson M, Young MK, Jamison CS, Gallagher J, Fitzgerald SP, Lamont J, and Watson CJ
- Subjects
- Biomarkers, Tumor, Hematuria diagnosis, Hematuria etiology, Humans, Vascular Endothelial Growth Factor A, Diabetes Mellitus, Type 2 complications, Renal Insufficiency, Chronic complications, Urinary Bladder Neoplasms complications, Urinary Bladder Neoplasms diagnosis, Urinary Bladder Neoplasms pathology
- Abstract
Aims: To identify clinical features and protein biomarkers associated with bladder cancer (BC) in individuals with type 2 diabetes mellitus presenting with haematuria., Materials and Methods: Data collected from the Haematuria Biomarker (HaBio) study was used in this analysis. A matched sub-cohort of patients with type 2 diabetes and patients without diabetes was created based on age, sex, and BC diagnosis, using approximately a 1:2 fixed ratio. Randox Biochip Array Technology and ELISA were applied for measurement of 66 candidate serum and urine protein biomarkers. Hazard ratios and 95% confidence intervals were estimated by chi-squared and Wilcoxon rank sum test for clinical features and candidate protein biomarkers. Diagnostic protein biomarker models were identified using Lasso-based binominal regression analysis., Results: There was no difference in BC grade, stage, and severity between individuals with type 2 diabetes and matched controls. Incidence of chronic kidney disease (CKD) was significantly higher in patients with type 2 diabetes (p = 0.008), and CKD was significantly associated with BC in patients with type 2 diabetes (p = 0.032). A biomarker model, incorporating two serum (monocyte chemoattractant protein 1 and vascular endothelial growth factor) and three urine (interleukin 6, cytokeratin 18, and cytokeratin 8) proteins, predicted incidence of BC with an Area Under the Curve (AUC) of 0.84 in individuals with type 2 diabetes. In people without diabetes, the AUC was 0.66., Conclusions: We demonstrate the potential clinical utility of a biomarker panel, which includes proteins related to BC pathogenesis and type 2 diabetes, for monitoring risk of BC in patients with type 2 diabetes. Earlier urology referral of patients with type 2 diabetes will improve outcomes for these patients., Trial Registration: http://www.isrctn.com/ISRCTN25823942., (© 2022 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF